Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Jefferies upgraded Royal Caribbean (RCL) to Buy with a $330 price target, citing improved occupancy and revenue per passenger. RCL trades at $282.32, with a P/E ratio of 17.66. Jefferies raised revenue estimates for Q3 2026 and FY 2027, projecting net yield growth and higher EBITDA. Despite lower EPS estimates, the firm increased valuation multiples. Other analysts also upgraded RCL, citing strategic developments and positive yield outlooks.

KeyBanc upgraded Generac (GNRC) to Overweight with a $280 price target, citing confidence in its $8B Amazon deal. GNRC stock is up 62% YTD. Analysts debate capacity ramp-up, but management is confident. Other firms also raised targets, while some lowered them due to execution concerns.

JPMorgan initiated coverage on Neurogene Inc. (NASDAQ: NGNE) with an Overweight rating and a $60.00 price target, citing potential in its gene therapy NGN-401 for Rett syndrome. The stock trades at $25.87, with analysts maintaining a Strong Buy consensus. Neurogene expects key data readouts in 2H27, with a market cap of $518 million and high volatility. Recent analyst adjustments include lowered price targets from H.C. Wainwright and Canaccord, both maintaining Buy ratings.

Biohaven (BHVN) has licensed IgG degraders to Ono Pharma for Japan and select Asian regions. The lead candidate, BHV-1300, is in Phase 3 trials for Graves' disease. The agreement marks a strategic partnership and late-stage pipeline update for Biohaven's immunology platform.

Biohaven (BHVN) has entered a licensing agreement with Ono Pharma for its extracellular IgG degraders in Japan and select Asian regions. Biohaven will receive up to $100 million in payments, including $80 million upfront, and 20% royalties on net sales. The lead candidate, BHV-1300, is in Phase 3 trials for Graves' disease. Biohaven retains rights to the portfolio outside the licensed territory.

Zealand Pharma's shares fell 3% despite reporting positive mid-stage trial results for its obesity drug petrelintide in type 2 diabetes patients. The trial met its main goal, with patients losing up to 9.2% body weight. The company plans further trials with Roche. According to Zealand, no unexpected safety issues were observed.